Targeted therapies in oncology;Thérapeutiques anticancéreuses ciblées

Revue de Medecine Interne

Volumn 27, Issue SUPPL. 3, 2006, Pages

  You, B ^a   Trillet Lenoir, V ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMPHIREGULIN; ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CETUXIMAB; CYTARABINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; IRINOTECAN; NEXAVAR; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; VASCULOTROPIN;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BLEEDING; BREAST CANCER; BRONCHUS CANCER; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG FEVER; DRUG HYPERSENSITIVITY; EPISTAXIS; HUMAN; HYPERTENSION; IMMUNOTHERAPY; METASTASIS; NAUSEA; ONCOLOGY; PROTEINURIA; SHOCK; THROMBOEMBOLISM; TREMOR; URTICARIA; VOMITING;

EID: 33751210595     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.09.012     Document Type: Article

References (16)

1. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 (2003) 994-1004
2. Rankin C. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST-Phase III Sarcoma Group Study S0033. Proc Am Soc Clin Oncol 2004. (abstract 9005). J Clin Oncol 22 (2004) (14S [July supplement])
3. Blanke C.D. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. Proc Am Soc Clin Oncol 2006. (abstract 9528). J Clin Oncol 24 (2006) (18S [June supplement])
4. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
5. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
6. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
7. Dang C. Updated cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA). Proc Am Soc Clin Oncol 2006. (abstract 586). J Clin Oncol 24 (2006) (18S [July supplement])
8. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (2004) 337-345
9. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
10. Shepherd F.A., Rodrigues P.J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353 (2005) 123-132
11. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
12. Giantonio B.J., Levy D.E., O'dwyer P.J., Meropol N.J., Catalano P.J., Benson A.B., et al. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200. Ann. Oncol. 17 9 (2006) 1399-1403
13. Yang J.C. Bevacizumab for patients with metastatic renal cancer: an update. Clin. Cancer Res. 10 (2004) 6367S-6370S
14. Motzer R.J. Phase III randomized trial of sunitinib malate (SU11248) vs interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 2006. (abstract LBA3). J Clin Oncol 24 (2006) (18S [July supplement])
15. Demetri G.D. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 2004. (abstract 3001). J Clin Oncol 22 (2004) (14S [July supplement])
16. Escudier B. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005. (abstract 4510). J Clin Oncol 23 (2005) (16S [July supplement])